Oyama, Genko
Burq, Maximilien
Hatano, Taku
Marks, William J. Jr
Kapur, Ritu
Fernandez, Jovelle
Fujikawa, Keita
Furusawa, Yoshihiko
Nakatome, Keisuke
Rainaldi, Erin
Chen, Chen
Ho, King Chung
Ogawa, Takashi
Kamo, Hikaru
Oji, Yutaka
Takeshige-Amano, Haruka
Taniguchi, Daisuke
Nakamura, Ryota
Sasaki, Fuyuko
Ueno, Shinichi
Shiina, Kenta
Hattori, Anri
Nishikawa, Noriko
Ishiguro, Mayu
Saiki, Shinji
Hayashi, Ayako
Motohashi, Masatoshi
Hattori, Nobutaka
Article History
Received: 13 October 2022
Accepted: 3 February 2023
First Online: 14 March 2023
Competing interests
: T.H. has received grants from: the Japan Agency for Medical Research and Development (grant numbers: 20dm0107156, 21wm0425015, 21ak0101112, and 21dk0207055), the Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research (grant number: 21K07424), the Setsuro Fujii Memorial Osaka Foundation for Promotion of Fundamental Medical Research, and Daiichi Sankyo TaNeDS; and research funds from: Daiichi Sankyo TaNeDS Funding Program. He has received speaker’s honoraria from: Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Company Limited, FP Pharmaceutical Corporation, Kyowa Kirin Co., Ltd., Nihon Medi-Physics Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd, and Otsuka Pharmaceutical Co., Ltd. N.N. has received grants from Grant-in-Aid for Scientific Research (Kakenhi) and Sumitomo Dainippon Pharma Co. Ltd. and honoraria from Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Company Limited, AbbVie GK, Kyowa Kirin Co., Ltd., and Ono Pharmaceutical Co., Ltd. N.H. has received consulting fees from GlaxoSmithKline K.K., AbbVie Inc., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Meiji Seika Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd, and FP Pharmaceutical Corporation; lecture fees from MSD K.K., Eli Lilly Japan K.K., Eisai Co., Ltd., FP Pharmaceutical Corporation, Otsuka Pharmaceutical Co., Ltd., Tsumura & Co., Kyowa Kirin Co., Ltd., GlaxoSmithKline K.K., Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Nihon Medi-Physics Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Dainippon Pharma Co. Ltd., and Daiichi Sankyo Company, Limited; honoraria from FP Pharmaceutical Corporation, Novartis Pharma K.K., Kyowa Kirin Co., Ltd., and AbbVie Inc.; research support from Otsuka Pharmaceutical Co., Ltd.; and grants from Astellas Pharma Inc., Eisai Co., Ltd., GlaxoSmithKline K.K., Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Company Limited, Novartis Pharma K.K., Pfizer Japan Inc., Kyowa Kirin Co., Ltd., Medtronic Japan Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Boston Scientific Corporation, Kissei Pharmaceutical Co., Ltd, and Otsuka Pharmaceutical Co., Ltd. G.O. has received grants from Grant-in-Aid for Scientific Research (Kakenhi) and Novartis Pharma K.K. and honoraria from AbbVie Inc., Boston Scientific Corporation, Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Medtronic Japan Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co. Ltd., and Takeda Pharmaceutical Company Limited. A.Hat, M.I., H.K., R.N., T.O., Y.O., F.S., K.S., H.T.-A., D.T., S.S., and S.U. have no conflicts of interest to disclose. M.B., C.C., K.C.S., R.K., W.J.M., and E.R. are employees and minor shareholders of Verily Life Sciences LLC. K.F., Y.F., A.Hay, M.M., and K.N. are employees of Takeda Pharmaceutical Company Limited. J.F. was an employee of Takeda at the time the work was conducted and is a minor shareholder of Takeda and GlaxoSmithKline.